- Home
- FENC vs DTIL Comparison
FENC vs DTIL Comparison
Compare FENC & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | DTIL |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 187.6M |
| IPO Year | 2010 | 2019 |
Fundamental Metrics
Financial Performance| Metric | FENC | DTIL |
|---|---|---|
| Price | $9.69 | $7.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $14.50 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 257.1K | 195.5K |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $44,642,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $65.12 | N/A |
| Revenue Next Year | $41.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $3.53 |
| 52 Week High | $10.27 | $8.82 |
Technical Indicators
Market Signals| Indicator | FENC | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 76.50 | 48.78 |
| Support Level | $7.45 | $6.50 |
| Resistance Level | $9.92 | $7.84 |
| Average True Range (ATR) | 0.61 | 0.59 |
| MACD | 0.35 | -0.13 |
| Stochastic Oscillator | 86.85 | 32.54 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).